Based on this preclinical evidence, a clinical trial to evaluate the safety and efficacy of the first‐line treatment with AXL inhibitor ONO7475‐03 and osimertinib in EGFR mutated NSCLC patients (jRCT2051210045) is currently ongoing. The gene discussed is AXL; the disease is non-small cell lung carcinoma.